More Than Medicine: iGenomeDx
Meet Dr. Niti Vanee
I’m so excited to dive into iGenomeDx and the incredible work that you and your team are doing. But before we do…congratulations on winning the 2025 NAWBO Women Business Owner of the Year award as well as the 2026 San Antonio Business Journal 40 Under 40 Award! Both so well deserved!
Okay, back to business, can you tell me about iGenomeDx? When did it start and what does it do?
iGenomeDx was founded in 2016 to expand access to precision medicine. We are a Texas-based, CLIA-certified and COLA-accredited molecular diagnostic lab specializing in pharmacogenomics, infectious disease testing, and toxicology. Our goal is to provide clinicians with clear genetic data that supports better treatment decisions.
Adverse drug reactions remain a major healthcare issue, contributing to over 1 million emergency visits annually in the U.S. Molecular diagnostics can help reduce that burden through informed prescribing and earlier detection.
Another congratulations on achieving 10 years in operation! Now, some people say you shouldn’t mix business with pleasure, what is it like owning a business with your spouse?
Building iGenomeDx with my spouse, Dr. Pramod Mishra has been one of the greatest professional privileges of my life. We bring complementary strengths. Clear communication and defined roles are essential. We respect each other’s expertise. Most importantly, we share a commitment to improving healthcare in our community.
What inspired you to pursue a career in healthcare? What drives your passion?
Healthcare combines science, service, and impact. Molecular diagnostics helps move care beyond symptom management toward root cause insight. What drives me most is seeing measurable results, especially when pharmacogenomic guidance helps improve a patient’s outcome. I feel fortunate to contribute to the continued growth of precision medicine.
Pharmacogenomics is a hot topic right now. What is it and why?
Pharmacogenomics studies how genetic differences influence the way individuals respond to medications. Research shows that nearly 90% of people carry at least one genetic variant that may affect how they metabolize commonly prescribed drugs.
Pharmacogenomic testing helps identify which medications may be more effective and which may carry a higher risk of side effects, supporting safer prescribing and better treatment outcomes. .
Is pharmacogenomics available to patients?
Yes. Pharmacogenomic testing is widely available through healthcare providers.
At iGenomeDx, the test is non-invasive and performed using a simple cheek swab.
Results are typically available within a few days and include a detailed clinical interpretation to assist prescribing decisions. Most insurance plans provide coverage when medically necessary. For patients paying out of pocket, we offer transparent self-pay pricing at $300.
You’re doing so much professionally, what are some hobbies or passions outside of work?
I am a mother of two young children. Much of my joy comes from being present with them.
I also value reading, travel, and early morning reflection routines. Leadership requires perspective and balance. These moments help me stay grounded and grateful.
Do you have anything coming up in 2026 that you would like to highlight?
San Antonio continues to grow as one of the most dynamic healthcare markets in the country. In 2026, my primary focus is to expand the access to pharmacogenomic testing within the San Antonio community and support local healthcare practices in optimizing medication management through precision medicine. We want to ensure that innovative tools are not limited to large academic centers but are available to everyday clinicians and their patients.
On a personal level, I will also be stepping into a leadership role with two nonprofit organizations dedicated to education and community engagement. This aligns closely with both my professional mission and personal values.
We are proud of what we have built since 2016, and deeply grateful for the trust of our partners and community. At the same time, we are energized by what lies ahead. Precision medicine is advancing quickly, and our responsibility is to ensure that innovation translates into real impact for the patients and providers who need it most.